Bottom line
IXJ vs ETHSX: the short answer
IXJ (iShares Global Healthcare ETF) and ETHSX (Eaton Vance Worldwide Health Sciences Fund) share a meaningful slice of their top holdings — about 74% by weight.
But IXJ is far broader, holding 124 positions to 42 for ETHSX, so beyond the top names it adds exposure ETHSX doesn't have.
IXJ is cheaper at 0.38% vs 1.18% — a difference of $80 a year per $10,000 invested.
Over five years, IXJ returned +6.4% a year vs +5.3% for ETHSX (reporting dates differ).
ETHSX has a front-end sales load of up to 5.25%; the other does not.
Updated Nov 19, 2026
IXJ vs ETHSX side by side
| IXJ | ETHSX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | iShares | Morgan Stanley |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.38% | 1.18% |
| Annual cost per $10k | $38 | $118 |
| 10-yr cost on $10k (prospectus) | $480 | $1,911 |
| Max front load | None | 5.25% |
| 12b-1 fee | 0% | 0.25% |
| 1-yr return | +14.9% | −1.9% |
| 5-yr return (annualized) | +6.4% | +5.3% |
| 10-yr return (annualized) | +8.2% | +6.4% |
| Best quarter | +13.6% | +14.2% |
| Worst quarter | −11.8% | −12.1% |
| Net assets (fund) | $3.8B | $757.9M |
| Number of holdings | 124 | 42 |
| Portfolio turnover | 2% | 3% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | IXJ | ETHSX | Difference |
|---|---|---|---|
| 2024 | +0.6% | +3.5% | −2.9% |
| 2023 | +3.5% | +5.7% | −2.2% |
| 2022 | −4.7% | −9.4% | +4.7% |
| 2021 | +19.5% | +22.1% | −2.6% |
| 2020 | +12.5% | +13.0% | −0.6% |
| 2019 | +23.4% | +26.0% | −2.6% |
| 2018 | +2.9% | +6.0% | −3.1% |
| 2017 | +20.3% | +16.2% | +4.1% |
| 2016 | −6.2% | −14.9% | +8.7% |
| 2015 | +5.9% | +8.4% | −2.5% |
Source: Fund prospectus bar charts
Holdings overlap
17 of IXJ's top 25 holdings also appear in ETHSX's top 25.
| Holding | IXJ | ETHSX |
|---|---|---|
| Eli Lilly And Company | 10.93% | 12.47% |
| Johnson & Johnson | 7.04% | 6.45% |
| Abbvie Inc. | 5.12% | 6.46% |
| Unitedhealth Group Incorporated | 4.40% | 5.49% |
| Merck & Co., Inc. | 4.12% | 5.08% |
| Astrazeneca Plc | 3.76% | 6.24% |
| Roche Holding AG | 3.75% | 5.44% |
| Novartis AG | 3.71% | 1.65% |
| Thermo Fisher Scientific Incorporated | 2.42% | 2.79% |
| Abbott Laboratories | 2.05% | 1.65% |
| Gilead Sciences, Inc. | 2.04% | 3.34% |
| Novo Nordisk A/s | 1.99% | 1.71% |
| Intuitive Surgical, Inc. | 1.83% | 2.72% |
| Vertex Pharmaceuticals Incorporated | 1.64% | 3.38% |
| Bristol-myers Squibb Company | 1.53% | 4.25% |
Source: SEC Form N-PORT
IXJ top 10
- Eli Lilly And Company — 10.93%
- Johnson & Johnson — 7.04%
- Abbvie Inc. — 5.12%
- Unitedhealth Group Incorporated — 4.40%
- Merck & Co., Inc. — 4.12%
- Astrazeneca Plc — 3.76%
- Roche Holding AG — 3.75%
- Novartis AG — 3.71%
- Amgen Inc. — 2.54%
- Thermo Fisher Scientific Incorporated — 2.42%
ETHSX top 10
- Eli Lilly & Co — 12.47%
- AbbVie Inc — 6.46%
- Johnson & Johnson — 6.45%
- AstraZeneca PLC — 6.24%
- UnitedHealth Group Inc — 5.49%
- Roche Holding AG — 5.44%
- Merck & Co Inc — 5.08%
- Bristol-Myers Squibb Co — 4.25%
- Vertex Pharmaceuticals Inc — 3.38%
- Gilead Sciences Inc — 3.34%
FAQ
What is the difference between IXJ and ETHSX?
Which is cheaper, IXJ or ETHSX?
Should I own both IXJ and ETHSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.